Methylation status of insulin-like growth factor-binding protein 7 concurs with the malignance of oral tongue cancer by Li-Hsuen Chen et al.
Chen et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:20 
DOI 10.1186/s13046-015-0138-5RESEARCH ARTICLE Open AccessMethylation status of insulin-like growth
factor-binding protein 7 concurs with the
malignance of oral tongue cancer
Li-Hsuen Chen1,2, Dai-Wei Liu2,3, Junn-Liang Chang4,5, Peir-Rong Chen3,6, Lee-Ping Hsu3,7, Hon-Yi Lin3,8,
Yu-Fu Chou3,6, Chia-Fong Lee3,6, Miao-Chun Yang3,6, Yu-Hsuan Wen3,6, Wen-Lin Hsu2,3* and Ching-Feng Weng1*Abstract
Background: Aberrant insulin-like growth factor-binding protein 7 (IGFBP-7) expression has been found in various
cancers such as prostate, breast, and colon. IGFBP-7 induced the apoptosis of tumor and potentially predicted the
clinical outcome in some cancers is further demonstrated. This study investigates the causes and underlying mechanisms
of aberrant IGFBP-7 expression in unravelling head and neck squamous cell carcinoma (HNSCC).
Methods: A total of 47 oral tongue cancer patient samples were primarily analyzed for the methylation status in
5′ region of IGFBP-7 by methylation-specific PCR (MS-PCR). Subsequently the invasion, overexpression, and knockdown
of IGFBP-7 in the HNSCC A253 invasive subpopulation were employed to examine the effect of IGFBP-7. The
epithelial–mesenchymal transition (EMT) marker genes and AKT/GSK3β/β-catenin signaling were further evaluated
by Western blot for the understanding the role of aberrant IGFBP-7 expression and thereof putative mechanism.
Results: EMT expressed in the invasive subpopulation of HNSCC cell lines (A253 and RPMI 2650) was contemporary
with the down-regulation of IGFBP-7. After treatment with 5-AZA-2′ deoxycytidine, the de-methylated CpG sites in the
5′ region of IGFBP-7 were observed and IGFBP-7 mRNA expression was also restored. Accordingly, re-expression
IGFBP-7 in invasive subpopulation of A253 could induce the mesenchymal–epithelial transition (MET) and concurrently
inhibited the cell invasion. Moreover, IGFBP-7 methylation status of 47 oral tongue tumors showed a positive
correlation to invasive depth of the tumor, loco-regional recurrence, and cancer sequence.
Conclusions: IGFBP-7 can alter EMT relative marker genes and suppress cell invasion in A253 cell through AKT/
GSK3β/β-catenin signaling. The epigenetic control of IGFBP-7 in the invasion and metastasis of HNSCC was
reported, suggesting that IGFBP-7 could be a prognostic factor for the probability of invasion and a therapeutic
remedy.
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Cancer of the head and neck can be categorized by the
area where it begins including the oral cavity, pharynx,
larynx, paranasal sinuses, and nasal cavity [1]. Head and
neck cancer is the sixth leading cancer by incidence
worldwide [2] and the most important risk factors for
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unless otherwise stated.alcohol and tobacco addiction [3]. Treatment of HNSCC
includes surgery, radiation therapy, chemotherapy, tar-
geted therapy, or a combination of treatments. Unfortu-
nately, the outcome of therapy in five years of overall
survival for the advanced stages of HNSCC is about 50%
and patients often suffer recurrences at the primary site
or distant metastases [4]. Hence, the related target mol-
ecule as a biomarker for HNSCC is crucial and urgent
for the strategy of clinical treatment.
Insulin-like growth factor-binding proteins (IGFBPs)
are one component of the insulin-like growth factor (IGF)
system. IGFBP-7 belongs to the IGFBP superfamily, alsohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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25, and is a member of the soluble protein family that
binds to IGFs with a low affinity [5]. IGFBP-7 is broadly
expressed in various tissues and organs, including the
brain, lung, prostate, bladder, liver, and colon [6]. The ex-
pression of IGFBP-7 is diminished in various types of hu-
man cancer cell lines, including prostate, breast, colon,
and lung cancer [7-10]. Moreover, the expression of
IGFBP-7 is detected in a favorable prognosis of breast
cancer [9]. In vitro studies have been demonstrated that
IGFBP-7 can induce apoptosis in many cancer cells [7,11],
e.g., breast and prostate cancer cells; and acts as a poten-
tial tumor suppressor against colorectal carcinogenesis.
Thereof, aberrant IGFBP-7 expression may contribute to
the biological behavior of tumors and the outcomes of
clinical. One report showed that recombinant IGFBP-7
(rIGFBP-7) can efficiently prompt apoptosis in human
melanoma cell lines [12]. Thus, IGFBP-7 may be an effi-
cacious anticancer agent and related experiments have
provided the evidence that IGFBPs possess both IGF-
dependent and -independent anti-tumor actions [7].
CpG islands (CpG-rich sequences), generally unmethy-
lated status in normal cells, are typically existing in the
promoter regions or exons of genes [13]. Aberrant DNA
methylation in CpG islands of tumor suppressor genes is
validated as a frequent molecular event in human car-
cinomas [14]. Moreover, the hyper-methylation of cyto-
sine in CpG islands is concomitant with the suppressed
initiation of gene transcription and leads to carcinogenesis
[15]. In one recent study, aberrant hyper-methylation of
tumor suppressor genes was demonstrated to contribute
the oral carcinogenesis [16]. Additionally, the hyper-
methylation of certain genes (CDKN2A, CDH13, FHIT,
WWOX, CDH1, and RASSF1A) in various carcinomas
such as lung cancer and HNSCC has been found to cause
poor progression [17-19].
Tumor metastasis is a process that involved a series
complicated deregulation of cell adhesion, extracellular
matrix integrity, survival, angiogenesis, lymphangiogen-
esis, and cell migration [20]. One of most relevant
changes that occurred during metastasis in a large num-
ber of carcinomas is through the epithelial-mesenchymal
transition (EMT). Some criteria have pointed out for
EMT both in vivo and in vitro [21] including a) acquisi-
tion of N-cadherin, Vimentin, beta-catenin, or transcrip-
tion factors (Snail, Slug and Twist); and b) loss of E-
cadherin (E-cad) or cytokeratin. One of the key mole-
cules in the process of EMT is E-cad and the transition
of phenotypes commonly involved in the down-regulation
of E-cad. E-cad functionally inactivated by different mech-
anistic events that comprise somatic mutation, transcrip-
tional repression, and promoter methylation. Restoring
E-cad in tongue squamous cell carcinoma through the
suppression of the EMT was recently reported [22].Vimentin, the type III microfilaments (IFs) had gained
much importance as a canonical marker of EMT [23]
and served as a potential biomarker for predicting me-
tastasis in malignant melanoma [24]. The molecules
which can regulate EMT like Snail [25] are broadly in-
vestigated in cancer research. Previously the potential
role of IGFBP-7 in cancer invasion has been reported
[26]. Moreover, IGFBP-7 is silenced by DNA methyla-
tion in colorectal and gastric cancers [27,28]. To our
best knowledge, the methylation status of IGFBP-7 in
HNSCC has yet to be elucidated particularly in invasion.
In this study, the invasive subpopulations of HNSCC
cell lines (A253-3, −5, and RPMI 2650–8) were per-
formed to investigate the unravelling causes and under-
lying mechanisms of aberrant in HNSCC. Our data
showed that the presence of EMT in invasive subpopu-
lations and the epigenetic control of the IGFBP-7 ex-
pression. To further confirm the role of IGFBP-7 in
metastasis of HNSCC, the effect of re-expression and
knockdown of IGFBP-7 in HNSCC cell line were exam-
ined. Moreover, clinical oral tongue samples were also
collected and analyzed to verify a correlation between




All human experiments were conducted in accordance
with the Helsinki Declaration of 1975, as revised in
2000. Before experiments were conducted, all samples
and clinical information were decoded and renumbered
with a serial number. The followed procedures have also
been approved by the Institution Review Board (IRB) of
the Buddhist Tzu Chi General Hospital (Number IRB
100–101).
Cell lines and clinical tissue sampling
Two HNSCC cell lines, A253 and RPMI 2650, were ob-
tained from the American Type Culture Collection
(ATCC). A253 maintained in McCoy's 5a Medium,
RPMI 2650 maintained in Eagle's Minimum Essential
Medium, both supplemented with 10% FBS and a 37°C/
5% CO2 atmosphere. The invasive subclones of HNSCC
cell lines were obtained following the method described in
previous study [29] with minor modification. In brief,
100 μl of 80 μg Matrigel (cat 354234, BD) was placed on
the upper chamber of the Transwell (24 well, 8 μm pore
size, BD) and incubated for one hour at 37°C. The cells
were then seeded on the Matrigel coated Transwell with-
out serum and 500 μl of complete medium was added into
the lower chamber. Cells were cultured for several days
until cells invaded through the membrane. Cells remained
on the upper chamber were wiped out using sterilized cot-
ton swabs and the subclone of invasive cells was harvested
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peated this process. The number following cell names in-
dicated how many times the cells were selected (A253-3:
selected for 3 times, A253-5: selected for 5 times, RPMI
2650–8: selected for 8 times).
A total of 47 oral tongue cancer samples were used for
testing the methylation status of the 5′ region of IGFBP-
7 by methylation-specific PCR (MS-PCR). All tumor
samples were dissected and stored in RNAlater at the
time of radical surgery. After the IRB’s approval, the
samples were re-sectioned and applied in this study. The
correlation of clinical outcomes and IGFBP-7 methyla-
tion were analyzed.
5-AZA-2′ deoxycytidine treatment
To analyze the demethylation effect and restoration of
IGFBP-7 expression, HNSCC cells were treated with
2 μM of 5-aza-2′-deoxycytidine (5′AZA) (Sigma, St
Louis, MO) for 96 h and replaced the medium with 5′
AZA every 48 h. Cells were washed by PBS and DNA
and RNA were extracted by following methods.
DNA extraction, bisulfite modification, MS-PCR and bisul-
fite genomic sequencing
The genomic DNA was isolated from cell lines and tis-
sue samples using QIAamp DNA Mini Kit (QIAGEN).
Two micrograms of genomic DNA was applied to bisul-
fite conversion and purified by EpiTect Fast Bisulfite
Conversion Kit (QIAGEN) according to the manufactur-
er's instructions. MS-PCR and bisulfite genomic sequen-
cing (BGS) were performed as previously described [30].
A total of 80 ng of bisulfite-modified DNA were used in
MS-PCR and BGS.
The methylated and unmethylated specific-PCR condi-
tions for IGFBP-7 were performed as denature at 95°C
for 15 min followed by 35 cycles at 95°C for 30 sec, 60°C
for 30 sec, 72°C for 30 sec and final elongation at 72°C
for 5 min. The PCR for the methylated and unmethy-
lated products were visualized and photographed on 2%
agarose gel. For BGS, PCR product was purified and
cloned into pCR 2.1 using TA Cloning Kit (Invitrogen).
For each PCR product, five clones were sequenced and
55 CpG sites were included into this analysis. The pri-
mer sequences and PCR product sizes were showed in
Additional file 1: Table S1.
RNA extraction, cDNA synthesis and quantitation PCR
Total RNA was isolated using the Trizol reagent
(Invitrogen, USA) according to the manufacturer’s instruc-
tions. Total RNA was incubated with DNase I for 15 min
at 37°C. One microgram of total RNA was applied into
reverse transcription reaction using First Strand cDNA
Synthesis Kit (Roche). One microliter of cDNA was
amplified in a total reaction volume of 20 μl containing100 nM gene specific primer and 10 μl of 2× SYBR®
Green PCR Master Mix (Applied Biosystems) using
StepOne Real-Time System (Applied Biosystems). The
Q-PCR experiment was performed in triplicate and the
mean values were used for calculations. The IGFBP-7
mRNA expression index was normalized with the ref-
erence gene GADPH using the comparative Ct method
(2-△CT) [31].Transfection of IGFBP-7 expression plasmid and siRNA
against IGFBP-7
Expression plasmid of human IGFBP-7 was purchased
from OriGene (#SC119176). Transient IGFBP-7 expres-
sion A253-5 cells (marked as “IGFBP-7”) were obtained
using Xfect® transfection reagent (Clontech) according
the manufacturer’s instructions. 5 × 105 of A253-5 cells
were seeded in a 60 mm dish and cultured overnight. A
total of 15 μg of plasmid was used for transfection pro-
cedure for each dish. A253-5 without transfection was
labeled as a control (C) and cells transfected with
pEGFP-N1 were marked as “Mock” in this study. For
siRNA transfection, negative control siRNA and siRNA
against IGFBP-7 (#s7241) were purchased from Invitro-
gen. Final concentration of both siRNAs at 30 nM was
used in the transfection to obtain “IGFBP-7 + NC si” and
IGFBP-7 + siRNA respectively.Western blot
Culture cells were washed with PBS and the total pro-
tein was extracted using ProteoJET Mammalian Cell
Lysis Reagent (Fermentas) according to the manu-
facturer’s instructions. Nuclear protein fraction was
prepared using Nuclear Extract Kit (Active Motif )
according to the manufacturer’s instructions. In gen-
eral, 20 μg total proteins were loaded onto 10% SDS-
polyacrylamide gels and then transferred onto PVDF
membranes after electrophoresis. The transferred
membranes were blocked with StartingBlock Blocking
Buffers (Thermo Scientific) for 10 min and incubated
with specific primary antibody against E-cadherin (BD),
Vimentin (BD), IGFBP-7, phospho T308 AKT1, AKT1,
phosphor S9 GSK3β, GSK3β (Abcam), β-catenin
(GeneTax), or β-Actin (Cell signaling) at 1:1000 dilu-
tions at 4°C overnight. The membranes then were
washed three times in Tris Buffered Saline with 0.1%
Tween-20 (TBST). Bands were detected using a horse-
radish peroxidase-linked second antibody and en-
hanced chemiluminescence reagents, according to the
manufacturer's protocol. Bands were record by film
and the intensity of the band was quantified with a GS-
800 calibrated densitometer (Bio-Rad), and calculated
as the optical density area of bands. The data were
conducted independently in triplicate.
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One hundred microliter of 80 μg Matrix gel was previ-
ously placed onto the upper chamber of 24 well Transwell
with 8 μm pore size at 37°C for 2 h and 5 × 104 cells with
200 μl of culture medium without FBS were seeded on the
gel. Five hundred microliter of complete medium was
added into the lower chamber of the Transwell. After 24 h
incubation, cells on the upper chamber of the Transwell
were wiped out using cotton swaps and the Transwell was
stained with Diff-Quik stain solution according to the
manufacturer's protocol. Five images were photographed
for each Transwell under 50 or 100× magnification. Cell
numbers were counted and the mean values were used
for calculations.
IGFBP-7 Immunohistochemistry
Immunohistochemistry was performed using the method
described previously [32] with minor modification. Four
μm sections from paraffin-embedded tissues were depar-
affinized and treated with 3% hydrogen peroxidase in
methanol. Heat-induced epitope retrieval was achievedFigure 1 Characterizations of invasive subpopulation of HNSCC cell li
subpopulations. Images show that the cells invaded through the Matrigel c
EMT related genes and IGFBP-7 in A253, RPMI 2650 and their invasive subp
to A253 or RPMI 2650, respectively. ** indicated p < 0.01; *** indicated p < 0by incubation in 0.01 M citrate buffer (pH 6.0) and
heated in a microwave oven (700 W) by two cycles of
5 min. The sections were then placed in a humidified
chamber with 10% normal horse serum (Dako) at room
temperature (RT) for 20 min and incubated with pri-
mary antibody against IGFBP-7 (1:20, goat polyclonal
IgG, sc-6064, Santa Cruz, USA) at RT for 1 h. The sec-
tions were rinsed with PBS and incubated with an ap-
propriate dilution of biotinylated anti-goat antibody
(Dako) at RT for 1 h, rinsed with PBS, and incubated
with avidin-biotin complex (Dako) at RT for 30 min.
The substrate chromogen, 3% amino-9-ethylcarbazone
(Dako) was developed for 5 to 8 min. The slides were
then counterstained with Mayer hematoxylin and
photographed. The positive control was sampled from
normal oral tongue epithelium tissue known to express
IGFBP-7.
Statistical analysis
For the in vitro study, data are present as mean ± SD.
Statistical analysis between the control and thenes. (A) The invasion assay of A253, RPMI 2650 and their invasive
oated membrane at a magnification of ×50. (B) Protein expression of
opulations. Expression index was normalized with beta-actin and ratio
.001.
Figure 2 Methylation analysis of IGFBP-7 promoter and effect of 5′AZA on HNSCC cell lines. (A) Illustration of 5′ region of IGFBP-7. Position
of CpG islands and primers for IGFBP7 methylation assay. (B) MSP assay for A253 and its invasive subpopulations. M indicated methylated
amplicon and U indicated unmethylated amplicon. (C) BGS of 5′ region in IGFBP-7 for A253 and its invasive subpopulations. Data are shown with
an average methylation percentage with or without 5′AZA treatment for A253 cells. (D) Restored IGFBP7 mRNA expression after 5′AZA treatment.
IGFBP-7 mRNA expression was detect using Q-PCR after treatment with or without 5′AZA in HNSCC cell lines. *** indicated p < 0.001.
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Figure 3 Overexpression of IGFBP-7 in A253-5 cell reverses EMT and suppress cell invasion. (A) Western blot results show up-regulated
E-cadherin and down-regulated Vimentin after overexpression IGFBP-7 in A253-5 and reversed by siRNA knockdown. (B) Invasion assay after
overexpression of IGFBP-7 in A253-5 cell. Images show that the cells invaded through the Matrigel coated membrane at a magnification of × 100. C:
A253-5, Mock: A253-5 transfected with pEGFP-N1, IGFBP7: Transient IGFBP-7 expression A253-5 cells, IGFBP7 + NCsi: Transient IGFBP-7 expression
A253-5 cells transfected with negative control siRNA, IGFBP7 + siRNA: Transient IGFBP-7 expression A253-5 cells transfected with siRNA against IGFBP7.
* indicated p < 0.05, ** indicated p < 0.01, *** indicated p < 0.001 compared with A253-5 Mock cells. # indicated p < 0.01, ### indicated p < 0.001
compared with IGFBP7 + NCsi.
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test. Significantly different data was labeled using *, com-
pared to “Mock”, and # compared to the negative
control siRNA group, respectively. A Single mark
represents p < 0.05, double marks represent p < 0.01,
and triple marks represent p < 0.001. Survival data
were calculated according to the Kaplan-Meier
method and were compared using the log-rank test.
Statistical analysis was performed using StatView
(version 5.0; SAS Institute, Cary, NC). A p value <
0.05 was considered statistically significant.Results
Invasive subclones of HNSCC cell present EMT and
down-regulation of IGFBP-7
Invasive subclones of HNSCC cell lines A253-5 and
RPMI 2650–8 have shown significantly higher cell mo-
bility when compared to the original cell line A253-0
and RPMI 2650–0. After 24 h incubation, only few cells
(<20) could migrate in 8 μm pore size toward the lower
side of membrane coated with Matrigel (Figure 1A). In
Figure 1B shows that E-cadherin was down-regulated
whereas Vimentin was up-regulated in A253-5 and
RPMI 2650–8 cells, revealing that the EMT presents in
HNSCC cell lines. Concurrently, the down-regulated
IGFBP-7 in both A253-5 and RPMI 2650–8 cells was
also validated.Methylation status of IGFBP-7 and retrieval of IGFBP-7
expression
Methylation status in the 5′ region of IGFBP-7 was ex-
amined by MS-PCR and BGS. In Figure 2A shows that
−500 to +500 sequences of transcription start site of
IGFBP-7 were analyzed. Additional file 1: Table S1 lists
the CpG islands covering transcription start site was
used to design primers and primer sets. We found the
5′ region of IGFBP-7 might be partially methylated be-
cause 124 bp amplicon of methylated specific PCR (M)
was presented in all A253 cells and abrogated after 5′
AZA treatment (Figure 2B). Alongside, genomic DNA
from normal human white blood cell (WBC) was ex-
tracted and treated with or without CpG Methyltransfer-
ase (M.SssI) in MS-PCR to serve as positive and negative
controls, respectively.The methylation status of 55 CpG sites in the 5′ re-
gion of IGFBP-7 was determined by bisulfite sequencing
of the A253 cells. In Figure 2C shows the average meth-
ylated CpG sites from 5 clones of A253 cells that were
analyzed. The original A253-0 cell presented only 5.8%
methylated CpG sites of the 5′ region in IGFBP-7
whereas the invasive subclones A253-3 and A253-5
showed around 24-37% methylated CpG sites of the 5′
region in IGFBP-7. Interestingly, the treatment of 5′
AZA led to the unmethylated CpG sites and restore
mRNA expression of IGFBP-7 in HNSCC cell lines
(Figure 2D).
Overexpression of IGFBP-7 induce MET and reduce cell
invasion
As we know the treatment of 5′AZA can cause the uni-
versal demethylation effect in all methylated genes. To
investigate the specific effect of IGFBP-7 on invasive
subclone of HNSCC, the expression plasmid of IGFBP-7
was transfected to A253-5 cells. After 24 h transfection,
the protein level of IGFBP-7 was 3 fold higher when
compared to the Mock, which indicated the success of
transfection (Figure 3A). Interestingly, E-cad was also
increased and contrarily Vimentin was decreased in
while IGFBP-7 was overexpressed. The change of these
two marker genes in overexpression of IGFBP-7 may
infer the occurrence of MET. Moreover, knockdown of
IGFBP-7 using siRNA technique in re-expression A253-5
cells showed the reversion of MET. This result further
suggested that IGFBP-7 might alter the expression of
EMT-relative genes.
These transfected cells were also evaluated the invasive
ability using the invasion assay. In Figure 3B shows that
the re-expression of IGFBP-7 in A253-5 cells revealed
dramatic repression of cell invasion when compared
with the Mock cells (p < 0.001). After the transfection
with siRNA to knockdown the expression of IGFBP-7,
the ability of invasion was restored when compared with
the negative control siRNA (p < 0.001).
Involvement of AKT-GSK3β pathway in IGFBP-7 induced MET
The AKT signaling is an important pathway in the
EMT [33-35]. We also found the phosphorylation of
AKT was higher in A253-5 when compared to A253 cells
(Figure 4A). Subsequently, the AKT and its downstream
Figure 4 Inactivate of AKT/GSK3β and reduce translocation of β-catenin in IGFBP-7 overexpression A253-5 cells. (A) Western blot
analyzed the phosphorylation of AKT (Thr 308) and GSK3β (Ser 9). (B) Western blot using protein from nuclear fraction is analyzed. C: A253-5,
Mock: A253-5 transfected with pEGFP-N1, IGFBP7: Transient IGFBP-7 expression A253-5 cells, IGFBP7 + NCsi: Transient IGFBP-7 expression A253-5
cells transfected with negative control siRNA, IGFBP7 + siRNA: Transient IGFBP-7 expression A253-5 cells transfected with siRNA against IGFBP7.
*** indicated p < 0.001 compared with A253-5 Mock cells. # indicated p < 0.01 compared with IGFBP7 + NCsi.
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Age at Diagnosis 54.3 ± 10.7 50.9 ± 7.6 0.267
Tumor Size (mm) 30.2 ± 13.8 27.1 ± 11.5 0.451
Invasion Depth (mm) 17.3 ± 10.3 9.7 ± 6.4 0.030*
AJCC Stage 0.437
Early (I-II) 10 7























First Cancer 20 15
Second Primary 11 1
Data are expressed as mean ± SD. *p < 0.05.
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underlying mechanism of IGFBP-7 induced MET. In
Figure 4A shows that persistently activated AKT phos-
phorylation and inhibited GSK3β cause the nuclear
translocation of β-catenin (Figure 4B). After re-expression
of IGFBP-7 in A253-5 cells, the phosphorylated AKT and
GSK3β were down-regulated that consequently caused
less translocation of β-catenin when compared to the
Mock cells (p < 0.001). Moreover, the inhibition of AKT/
GSK3β/β-catenin signaling might be partially re-activated
by transfection of siRNA against IGFBP-7.
Clinical Studies
The expression of IGFBP-7 in oral tongue tumor lesions
is validated by immunohistochemical staining. Additional
file 2: Figure S1 shows the normal epithelium of oral
tongue tissue expresses IGFBP-7. The pathologic stage
of the IGFBP7 IHC positive case is T2N2bM0. Com-
pared with different AJCC (American Joint Committee
on Cancer) stage of tumor, the advance tumor lesions
(T4aN2bM0) showed the absence of IGFBP-7 expres-
sion. Subsequently, 47 oral tongue tumor lesions were
also performed to analyze the IGFBP-7 methylation
status by MS-MSP. There were 31 methylated and 16
unmethylated in 5′ region of IGFBP-7 (Table 1). Table 1
illustrates the clinic-pathological factors related to
IGFBP-7 methylation status. The clinic-pathological
factors are correlated to IGFBP-7 methylation status.
The data indicated the methylation status of IGFBP-7
was associated with invasive depth, loco-regional
recurrence and cancer sequence (p = 0.03, 0.011 and
0.029, respectively).
The disease-free survival (DFS) in patients with
methylated IGFBP-7 (1/2/4 year: 85%/ 58%/ 40%) was
significantly poorer than those of patients with
unmethylated IGFBP-7 (1/2/4 year: 100%/ 100%/ 80%)
(p = 0.025) (Figure 5). Furthermore, univariate and multi-
variate analyses showed that the AJCC stage of tumor and
methylation status of IGFBP-7 was significantly correlated
with DFS (Additional file 3: Table S2).
Discussion
The insulin-like growth factor (IGF) pathway is involved
in many cellular progression including proliferation, dif-
ferentiation, cell survival, tumor invasion and metastasis,
and inhibition of apoptosis [36,37]. Circulating IGFs are
binding to high affinity IGF binding proteins (IGFBP-1
to 6) to maintain IGFs bioactivity in extracellular fluids.
Recently, there are numerous studies demonstrated the
IGF-independent actions of IGFBPs. Especially, IGFBP-3
[38] and IGFBP-5 [39] show their tumor suppressor
character in HNSCC. In the present study provides first
evidence the down-regulation of IGFBP-7 by hyper-
methylation in HNSCC cell lines. The data show thatthe invasive phenotype of subpopulation in the HNSCC
cell lines is accompanied by the down-regulation of
IGFBP-7. This scenario was also validated in 47 oral
tongue tumor lesions by analyzing IGFBP-7 expression
and its promoter methylation status. Taken together, the
results suggest that the decreased expression of IGFBP-7
in HNSCC is regulated by DNA methylation. Although
some reports demonstrate the anti-tumor effects of
IGFBP-7 including cell growth inhibition [7,40],
Figure 5 Survival analysis of oral tongue patients with methylation status of IGFBP-7 promoter region.
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study is evident that the down-regulation of IGFBP-7 in
invasive HNSCC cell lines which show EMT feature. In
pervious report has suggested the potential role of
IGFBP-7 in cancer invasion [26,44]. Aberrant hyper-
methylation of tumor suppressor genes are well known
to contribute to oral carcinogenesis [16]. Moreover,
adenovirus expressing IGFBP7 has proof it anti-
metastasis effect on Hepatocellular carcinoma by xeno-
graft models [45]. Taken all known information into
considerations, the expression of IGFBP-7 seems to play
a vital role involved in the invasion and metastasis of
HNSCC.
Demethylating agents are used to result in the hypo-
methylation of DNA by inhibiting DNA methyltransfer-
ase, such as 5-aza-2′-deoxycytidine (5′AZA), which is
also chose to test its effect in the present work. Treated
A253 cells with 5′AZA can inhibit IGFBP-7 promoter
methylation and renovate the expression of IGFBP-7 but
might also cause the re-expression of other tumor sup-
pressor genes since 5′AZA is considered as an anti-
tumor agent [46]. Next, the over-expression of IGFBP-7
in invasive A253-5 cell is employed to study the anti-
invasive effect of IGFBP-7. Our results indicated dramatic
(p < 0.001) repression of cell invasion in the re-expression
of IGFBP-7 in A253-5 cells. When siRNA was employed
to knockdown the expression of IGFBP-7, the ability of in-
vasion was significantly (p < 0.001) restored. These results
reveal that IGFBP-7 plays a pivotal role of invasion control
in HNSCC.
The up-regulation of E-cad, down-regulation of
Vimentin, and inhibition of cell growth and invasiveness,suggesting the presence of MET in IGFBP-7 overex-
pressed A253-5 cells. Additionally, the inactivation of
AKT is also noted in IGFBP-7 overexpressed A253-5
cells. In general, AKT modulates numerous processes
characteristic of cancer including cell survival, cell cycle
regulation and apoptosis [47-49]. Activated AKT can
also induce EMT and increase the invasiveness of squa-
mous cell carcinoma [33]. AKT-induced EMT is re-
ported through the up-regulated expression of Snail
which is one of the E-cad transcriptional repressors
[50,51]. The involvement of another important pathway
GSK3β/β-catenin axis in AKT-induced EMT is demon-
strated [34]. GSK3β, one of AKT substrate, can inhibit
its activity by serine phosphorylation (Ser9). Firstly, the
inhibition of GSK3β in turn stabilizes Snail from the
degradation [52]. Secondly, the phosphorylation of
GSK3β at Ser9 can thwart the phosphorylating β-catenin
and stabilize β-catenin in the cytoplasm [53]. After β-
catenin accumulation, there was an increase in the tran-
scriptional activity while it translocated from cytoplasm
into the nucleus for binding transcriptional factors like
T-cell factor/lymphoid enhancer factor family (TCF/LEF)
[54]. The numbers of cellular oncogenes such as c-MYC,
cyclin D1, and the EMT-related genes Slug and Vimentin
are also regulated in this fashion [55-57].
Recent study in searching prognostic marker of HNSCC,
tissue microarrays were performed to show that Ki67
expression was associated with worse prognosis and
lymph node metastasis [58]. A meta-data analysis im-
plies that aldehyde dehydrogenase 1 (ALDH1)-positive
patients had worse prognosis including the decrease of
overall survival and disease-free survival [59]. SIRT6
Chen et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:20 Page 11 of 12and SIRT7 were altered in peripheral blood leukocytes
of HNSCC, implying they are potential circulating prog-
nostic markers for HNSCC [60]. Furthermore, parathy-
roid hormone-like hormone (PTHLH) which encodes
parathyroid hormone-related protein (PTHrP) could
play a character in the pathogenesis of oral squamous
cell carcinoma by interfering cell proliferation and cell
cycle, and the protein levels of PTHrP might potentially
serve as a prognostic indicator for the evaluating patients
with HNSCC [61]. As herein we report that IGFBP-7 may
serve a biomarker for prognosis of HNSCC, the in vitro
studies also reveal the underline mechanism of IGFBP-7
involved in invasion of HNSCC.
Conclusion
We report that IGFBP-7 can alter EMT relative marker
genes and suppress cell invasion in A253 cell through
the inhibition of AKT activation. Aberrant hyper-
methylation of IGFBP-7 in oral tongue tumors was signifi-
cantly concomitant with tumor progression (invasive
depth, loco-regional recurrence, and cancer consequence)
and poor prognosis. These results suggest that IGFBP-7
plays a potential role in regulating malignant behavior of
head and neck squamous cell carcinoma and may be a
novel therapeutic target for determination in the progres-
sion of HNSCC patients.
Additional files
Additional file 1: Table S1. Supporting Information Table S1 PCR
primers used in this study.
Additional file 2: Figure S1. Immunohistochemistry of IGFBP-7 in oral
tongue specimen (A, B, and C). Black arrow shows IGFBP-7 expression in
oral tongue specimen. Histology of oral tongue specimen using
hematoxylin and eosin stain (D, E, and F). The pathologic stage of IGFBP7
positive specimen (B and E) is T2N2bM0. The pathologic stage of IGFBP7
negative specimen (C and F) is T4aN2bM0. Images show at a magnification
of × 200.
Additional file 3: Table S2. Supporting Information Prognostic factors
of disease-free survival in oral tongue patients.
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